Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Fulcrum Therapeutics Inc FULC

Healthcare
Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. The Company’s clinical product candidate, losmapimod, is developed for the potential treatment of facioscapulohumeral muscular dystrophy (FSHD). Its other clinical product candidate is FTX... see more

Recent & Breaking News (NDAQ:FULC)

Fulcrum Therapeutics Announces Proposed Public Offering of Common Stock

GlobeNewswire August 10, 2021

Fulcrum Therapeutics Reports Recent Business Highlights and Second Quarter 2021 Financial Results

GlobeNewswire August 10, 2021

Fulcrum Therapeutics Announces Positive Interim Results from Phase 1 Healthy Adult Volunteer Trial of FTX-6058 for Sickle Cell Disease

GlobeNewswire August 10, 2021

Fulcrum Therapeutics to Host Second Quarter 2021 Financial Results Conference Call and Webcast on Tuesday, August 10, 2021 at 8:00 a.m. ET

GlobeNewswire August 4, 2021

Fulcrum Therapeutics Announces Results from ReDUX4 Trial with Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD) Demonstrating Slowed Disease Progression and Improved Function

GlobeNewswire June 24, 2021

Fulcrum Therapeutics Announces Multiple Presentations at the 28th Annual FSHD Society International Research Congress (IRC)

GlobeNewswire June 21, 2021

Fulcrum Therapeutics Announces U.S. Food and Drug Administration Grants Fast Track Designation to Losmapimod for the Potential Treatment of Facioscapulohumeral Muscular Dystrophy (FSHD)

GlobeNewswire May 12, 2021

Fulcrum Therapeutics to Present at the BofA Securities 2021 Virtual Health Care Conference

GlobeNewswire May 7, 2021

Fulcrum Therapeutics Reports Recent Business Highlights and First Quarter 2021 Financial Results

GlobeNewswire May 6, 2021

Fulcrum Therapeutics Appoints Christopher Morabito, M.D. as Chief Medical Officer

GlobeNewswire May 6, 2021

Fulcrum Therapeutics to Host First Quarter 2021 Financial Results Conference Call and Webcast on Thursday, May 6, 2021 at 8:00 a.m. ET

GlobeNewswire April 29, 2021

Fulcrum Therapeutics Presents Published Structure of Investigational Small Molecule FTX-6058 at the American Chemical Society (ACS) Spring 2021 Virtual Conference

GlobeNewswire April 9, 2021

Fulcrum Therapeutics Appoints Judith A. Dunn, Ph.D. as President of Research and Development

GlobeNewswire March 24, 2021

Fulcrum Therapeutics Presents Data for Potential FSHD Biomarker and Clinical Outcome Assessments at 2021 Muscular Dystrophy Association (MDA) Virtual Clinical & Scientific Conference

GlobeNewswire March 18, 2021

Fulcrum Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2020 Financial Results

GlobeNewswire March 4, 2021

Fulcrum Therapeutics Announces CEO Transition

GlobeNewswire March 4, 2021

Fulcrum Therapeutics to Host Fourth Quarter and Full Year 2020 Financial Results Conference Call and Webcast on Thursday, March 4, 2021 at 8:00 a.m. ET

GlobeNewswire February 26, 2021

Fulcrum Therapeutics Recognizes Rare Disease Day 2021

GlobeNewswire February 26, 2021

Fulcrum Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire February 19, 2021

Fulcrum Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares

GlobeNewswire January 22, 2021